DKK1 and arthritic joint disease: In experimental arthritis, neutralization of DKK-1 with an antibody inhibited bone erosion without affecting inflammation [42], whereas the neutralization of sclerostin improved systemic bone loss, but did not affect disease severity or focal bone erosions in the CIA model [50].